Realizing the benefits of regenerative medicine will require a structural shift toward earlier detection and therapeutic intervention.

Amphista Therapeutics (“the Company” or “Amphista”), a leader in the discovery and development of non-cereblon/non-VHL Targeted Glue™ degraders, today announces three upcoming presentations at the ...

Mayo Clinic in Arizona has two campuses. The largest is in north Phoenix, where a big expansion is underway. Here's what to ...

Record-Breaking Revenue of HK$586.2M and EPS Surged to HK$1.56 Cents Dividends Distributed for Two Consecutive Years Embarks on Innovation-Driven Transformation ...

Goldman Sachs 9th Annual Biopharma Innovation Summit March 26, 2026 5:00 AM EDTCompany ParticipantsKaivan Khavandi - Senior VP, Global Head ...

The 7 mg dose of OV329 demonstrated favorable safety and tolerability profile, reinforcing best-in-category potential for ...

A registry study across 14 Japanese clinics analyzed 179 cases of post-COVID-19 vaccination syndrome (PCVS) and identified ...

At a General Meeting on 11 June 2025, shareholders approved the subdivision and redesignation of the Company’s Issued ...

Curi Bio, a world leader in human-relevant 3D tissue technology, and Battelle, the world’s largest independent nonprofit research and development organization, today announced a strategic partnership ...

Good morning, and welcome to Sarepta's preliminary data readout of its Phase I/II studies for DM1 and FSHD. As a reminder, today's program is being recorded. At this time, I'll turn the call over to ...

Author Jo Giese outlines in her new book how, after a botched surgery, she lost her left Achilles and relearned to walk ...

Biodexa Pharmaceuticals PLC Stephen Stamp, CEO Fiona Sharp, CFO Tel: +44 (0)29 2048 0180 The Company's lead development programs include eRapa, under development for Familial Adenomatous Polyposis and ...